1. In Vivo
  2. >>Deal-Making

Dealmaking Quarterly Statistics, Q2 2020

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2020

 
• By Deanna Kamienski and Maureen Riordan

During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.

Quarterly Stats_1200x675

Biopharma merger and acquisition value for the second quarter of 2020 reached $5.9bn, a 14% decline from Q1’s $6.9bn (see Exhibit 1). At the top (making up about a third of this total) was Novo Nordisk AS’s $2.1bn buy of private US biotech Corvidia Therapeutics [See Deal] Novo is paying $725m in cash up front and could provide earn-outs of up to $1.375bn upon the achievement of milestones tied to Corvidia's ziltivekimab, its Phase II candidate for chronic kidney disease. Also see "Novo Nordisk Fortifies Cardio-Renal Efforts With Corvidia Buy" - Scrip, 11 June, 2020.

Exhibit 1.

More from Deal-Making

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.